Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers.

Journal of the American Heart Association

Volumn 3, Issue 2, 2014, Pages

  Flaim, Joann D ^a   Grundy, John S ^b   Baker, Brenda F ^b   McGowan, Mary P ^b   Kastelein, John J P ^b  

^a ISIS PHARMACEUTICALS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; INHIBITOR; MIPOMERSEN; OLIGONUCLEOTIDE;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; BLOOD; CANADA; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSING; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; HUMAN; INFLAMMATION; MALE; MIDDLE AGED; NORMAL HUMAN; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; YOUNG ADULT;

DOSING; INHIBITOR; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; SAFETY;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL AVAILABILITY; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; QUEBEC; TIME FACTORS; YOUNG ADULT;

EID: 84904663172     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.113.000560     Document Type: Article

References (0)